Abstract
Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for preventive treatment of migraine in adults. A prior database study found claims for acute medication were reduced 6 months post-initiation of fremanezumab versus 6 months pre-initiation. Twelve-month post-initiation data are now available. Changes in acute medication use in the 12 months prior to fremanezumab initiation and during a 12-month follow-up period were retrospectively analyzed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
